Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.

about

Jungermannenone A and B induce ROS- and cell cycle-dependent apoptosis in prostate cancer cells in vitro.A novel cabazitaxel-loaded polymeric micelle system with superior in vitro stability and long blood circulation time.

P2860

Q37112305-904F99C1-1155-4EA2-B4E4-AB17C6CE3CB5 Q38791156-F2F13634-3E94-400F-B476-A14415B90BF7

P2860

Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.

Item

http://www.wikidata.org/entity/Q48037116

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.

@en

Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.

@nl

type

Item

label

Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.

@en

Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.

@nl

prefLabel

Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.

@en

Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.

@nl

P1476

Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.

@en

P2093

Anuradha Jayaram

http://www.w3.org/2001/XMLSchema#string

P2860

Abiraterone in metastatic prostate cancer without previous chemotherapy

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union.

Enzalutamide in metastatic prostate cancer before chemotherapy.

Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms.

Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

P2888

nrurol.2015.98

P304

312-313

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRUROL.2015.98

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gerhardt Attard

P577

2015-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26032550

http://www.w3.org/2001/XMLSchema#string

Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.

about

P2860

P2860

Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P698